Lymphoma Clinical Trials 2024

Lymphoma Clinical Trials 2024

Lymphoma research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in lymphoma clinical trials today.

Lymphoma Clinical Trials

Here are the 6 most popular medical studies for lymphoma

Popular filter options for lymphoma trials

Burkitt Lymphoma Clinical Trials

View 60 Burkitt Lymphoma medical studies.

Cutaneous T-Cell Lymphoma Clinical Trials

View 60 Cutaneous T-Cell Lymphoma medical studies.

Lymphoma Clinical Trials With No Placebo

View 63 lymphoma medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to lymphoma

What are the top hospitals conducting lymphoma research?

When it comes to cutting-edge clinical trials in the field of lymphoma, several top hospitals are making significant strides. In New york City, the Memorial Sloan Kettering Cancer Center stands out with an impressive 10 active trials focused on lymphoma and a remarkable 238 completed studies throughout their history. This esteemed institution first ventured into lymphoma research back in 1995, demonstrating their longstanding commitment to understanding and treating this complex disease.

Meanwhile, on the East Coast in Boston, another renowned hospital is contributing greatly to lymphoma research. The Dana Farber Cancer Institute currently has seven active clinical trials dedicated to lymphoma and a noteworthy track record of 108 completed studies since initiating their first trial in 2000. Their expertise and dedication have made them a key player in advancing our knowledge of this challenging condition.

In Houston, Texas, two prestigious institutions are at the forefront of innovative lymphoma trials. The MD Anderson Cancer Center boasts six active clinical trials focused specifically on lymphoma treatment options while having conducted an impressive total of 144 previous investigations since launching its inaugural trial in 2001. Another branch of MD Anderson Cancer Center located within Houston also showcases similar dedication towards combating this disease with six ongoing explorations complemented by149 previously held trials dating back as early as1998.

On the West Coast lies Cedars-Sinai Medical Center situated in Los Angeles—a crucial contributor to advancing our understanding of lymphomas through diligent efforts and relentless innovation over time; they presently undertake four progressive clinical examinations alongside twenty-two prior endeavors—inaugurating their foray into these important investigations from as far back as1997.

These leading hospitals across different regions demonstrate a shared goal: pushing boundaries and seeking breakthroughs that can ultimately improve outcomes for those affected by lymphomas worldwide. By participating actively in these groundbreaking clinical trials, patients gain access to potentially life-saving treatments while paving the path for future advancements against this formidable disease

Which are the best cities for lymphoma clinical trials?

When it comes to lymphoma clinical trials, several cities stand out as hubs for cutting-edge research and treatment development. Houston, Texas leads the way with 35 active trials focusing on various treatments such as maplirpacept (PF-07901801) + an anti-CD20 targeting agent and EBV-specific T cells. Los Angeles, California follows closely behind with 25 ongoing studies exploring innovative approaches like maplirpacept (PF-07901801) + an anti-CD20 targeting agent and subprotocol C2 for MET exon 14 deletion/mutation. New york City also plays a significant role with 22 active trials investigating treatments including maplirpacept (PF-07901801) + an anti-CD20 targeting agent and ASTX660. These cities, along with Boston, Massachusetts (20 active trials) and Denver, Colorado (17 active trials), offer individuals facing lymphoma access to advanced clinical trials that pave the way for improved care options and better outcomes.

Which are the top treatments for lymphoma being explored in clinical trials?

Exciting advancements in lymphoma research are being made through rigorous clinical trials. Leading the way is rituximab, a well-established treatment with two active trials and an impressive history of 215 all-time lymphoma studies since its introduction in 1997. Additionally, another form of rituximab is also showing promise, currently involved in two ongoing trials and having been extensively studied with 588 all-time lymphoma trials since 1993. A newcomer on the scene is Biomarker Guided Intervention, which has shown potential in one active trial so far but holds great promise for future breakthroughs. These innovative treatments offer hope to patients battling this challenging disease and inspire optimism about improved outcomes in the years to come.

What are the most recent clinical trials for lymphoma?

Exciting advancements in the field of lymphoma research provide hope for improved treatment options. Prominent among the recent clinical trials is a Phase 1/Phase 2 study exploring dose escalation strategies to enhance therapeutic outcomes. Additionally, an innovative approach involving anti-CD30 bispecific antibody-armed anti-CD3 activated autologous T-cells (CD30 biAb-AATC) shows promise in targeting lymphoma cells specifically. Moreover, ongoing investigations into the efficacy and safety of Heplisav-B offer potential benefits for individuals with lymphoma. Another area of focus is stereotactic body radiation therapy, which aims to optimize treatment delivery and minimize side effects. Lastly, Glofitamab demonstrates its potential as a valuable therapeutic option through a comprehensive Phase 2 trial. These diverse studies pave the way towards more effective interventions and better prognoses for those affected by lymphoma.

What lymphoma clinical trials were recently completed?

Multiple clinical trials for lymphoma have recently reached significant milestones, signaling progress in the search for more effective treatments. In September 2021, the University of Chicago completed a trial investigating CC-486 as a potential therapy option. Additionally, the National Cancer Institute concluded their study on mRNA-1273 in April 2021. Moreover, the University of Colorado, Denver wrapped up their trial exploring Ublituximab in November 2020. These recent advancements highlight ongoing efforts by researchers to advance treatment options and provide hope for individuals battling lymphoma.